Research Article

1′H-Indole-3′-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor’s Regulation of Cytoskeletal Contraction

Lijiao Zhao, Qiuting Shu, Hui Sun, Yunlong Ma, Dandan Kang, Yating Zhao, Jing Lu, Pei Gong, Fan Yang, and Fang Wan

Department of Pharmaceutical Engineering, Inner Mongolia Agricultural University, Hohhot 010018, China

Correspondence should be addressed to Fang Wan; fwan@imau.edu.cn

Received 25 June 2020; Revised 10 August 2020; Accepted 24 August 2020; Published 5 October 2020

Guest Editor: Jialiang Yang

Copyright © 2020 Lijiao Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Blocking glioma cell invasion has been challenging due to cancer cells that can swiftly switch their migration mode, and agents that can block more than one migration mode are sought after. We found that small molecule 2-(1H-indole-3-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), an endogenous aryl hydrocarbon receptor (AHR) agonist, can block more than one mode of glioma cell migration, based on cultured cell behavior captured by videos. Data from wound-healing assays and mouse xenograft glioma models corroborated ITE’s migration-inhibiting effects while knocking down AHR by siRNA abolished these effects. To identify genes that mediated ITE-AHR’s effect, we first collected gene expression changes upon ITE treatment by RNA-seq, then compared them against literature reported migration-related genes in glioma and that were potentially regulated by AHR. MYH9, a component of nonmuscle myosin IIA (NMIIA), was confirmed to be reduced by ITE treatment. When MYH9 was overexpressed in the glioma cells, a good correlation was observed between the expression level and the cell migration ability, determined by wound-healing assay. Correspondingly, overexpression of MYH9 abrogated ITE’s migration-inhibiting effects, indicating that ITE-AHR inhibited cell migration via inhibiting MYH9 expression. MYH9 is essential for cell migration in 3D confined space and not a discovered target of AHR; the fact that ITE affects MYH9 via AHR opens a new research and development avenue.

1. Introduction

Glioblastoma (GBM), the most common and advanced form of glioma, is one of the most lethal human cancers. GBM patients survive, on average, 12–15 months despite aggressive surgical resection, radiation, and chemotherapy [1]. The diffuse invasion of the GBM tumor cells and the blood-brain barrier pose major challenges for successful therapy since invaded tumor cells are sheltered from complete surgical removal and radiation. Targeted drug discovery concentrates on the receptor and signaling pathway, such as EGFR, VEGFR, PDGFR, MET, MEK, and molecules that mediate cell interaction with the ECM, such as integrin and syndecan.

We targeted AHR, a ligand-activated transcription factor, and E3 ubiquitin ligase. AHR regulates cytotoxic immune cells in cancer by controlling the function and differentiation of multiple types of immune cells. In glioma, AHR is expressed in glioma and the stromal cells, including endothelial cells, astrocytes, oligodendrocytes, microglia, macrophages, dendritic cells, and T lymphocyte [2–4]. AHR’s effects on cancer are complex, highly depends on the ligands in the microenvironment and the cell types. Glioma, its reported that AHR regulated tumor cell migration and may serve as a tumor suppressor [5].

We found that targeting AHR in glioma blocked glioma invasion. The majority of endogenous AHR ligands are tryptophan metabolites, and the most abundant tryptophan metabolite in glioma is kynurenine, which is produced by enzymes 2,3-dioxygenase (IDO/TDO), binds to AHR and inhibits cytotoxic immune cell activity against glioma cells [6], forming a pathway of Tryptophan-Kynurenine-AHR-Impairment of Immunity. To block this pathway, inhibitors
for the IDO/TDO were developed and mixed clinical trial results have been posted [7, 8], not meeting expectations. An alternative route is to directly target AHR using small-molecule ligands. We hypothesized that targeting AHR using a high-affinity agonist could achieve this goal while maintaining AHR’s tumor suppressor effects in glioma. To this end, we tested the effects of ITE, an endogenous AHR agonist, and discovered that ITE significantly inhibited glioma cell migration and invasion.

We report that ITE can significantly block glioma cell migration and invasion in wound healing and transwell assay, in brain invasion assay, and in a mouse model. In a 3D collagen matrix, in addition to the more dynamic filopodia, ITE induced weaker protrusion attachment to the ECM. In 2D cultures, glioma cells failed to undergo amoeboid dia, ITE induced weaker protrusion attachment to the ECM.

2. Materials and Methods

2.1. Cell Culture. Human and mouse glioma cell lines U87MG and GL261 were obtained from the National Infrastructure of Cell Line Resource and the Third Military Medical University, respectively. U87MG and GL261 cells were cultured using MEM/EBSS and DMEM/F12 supplemented with 10% FBS, respectively.

2.2. Cell Invasion and Migration Assays. Boyden chamber (CORNING, USA) was coated with 30 μl rat tail tendon collagen type I (PERFEMIKER, #C20-200110), incubated for 30 min at 37°C. 5 × 10^4 cells were seeded into chambers and cultured in DMEM/F12 with 2% FBS, and the lower chamber medium contains 10% FBS. After 20 hr, cells were fixed with 4% paraformaldehyde, and the nonmigrated cells were removed with cotton swabs. The migrated cells on the bottom were stained with crystal violet and counted. Invasion assays were repeated six times over multiple days.

For the wound-healing assay, horizontal lines were drawn on the back of 12-well plates at a spacing of 0.5~1 cm using a marker pen, with at least 5 lines pass through each well plate. When cells were grown to 70% confluence in 12 well tissue culture dish, a single scratch was made perpendicular to the horizontal lines, using a 10 μl pipette tip. Cells were then rinsed with PBS and incubated in serum-free medium with different concentrations of ITE (0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM, and 10,000 nM) or 0.02% DMSO (SIGMA, #D5879) for 20 hr. Images were captured at 0 hr and 20 hr at the same position of cross points of horizontal lines and scratch. Using ImageJ, the wound in each image was identified using the magic wand tool, and the area measured by the ROI function. Wound-healing assays were carried out in three batches of the experiment. In a batch, each treatment was replicated in three wells, quantified by measuring two or three fields per well.

2.3. Mouse Orthotopic Glioma Model. All experiments were performed following the animal care guidelines of Inner Mongolia Agricultural University.

8-week-old C57BL/6 mice (Beijing Vital River Laboratory Animal Technology Co. Ltd) were anesthetized with an intraperitoneal injection of 0.3% pentobarbital sodium (30 mg/kg). For the stereotactic intracranial injection, the surgical site was shaved and prepared with iodine. A midline incision was made to expose the bregma point, and a 1 mm diameter right parietal burr hole was drilled with a dental drill, centered at 2 mm posterior to the coronal suture and 2 mm lateral to the sagittal suture. Mice were placed in a stereotactic frame and 1 × 10^3 GL261 cells in 2.5 μl medium were intracranially injected at a depth of 3 mm using Micro-injection Pump (KD scientific, 78-1311Q) at a speed of 0.5 μl/min. The needle was removed slowly, and the skin was sutured with nylon thread.

2.4. Hematoxylin and Eosin Stain of the Mouse Brain Tissue. Mice were anesthetized and perfused with 4% paraformaldehyde (PFA) through the right atrium. Brains were harvested and placed in 4% PFA for 12 hr, then in 15%, 20%, and 30% sucrose solutions consequently for 12 hr each. Tissue was embedded in Optimal Tissue Cutting Compound (OCT® SAKURA) and frozen in liquid nitrogen. Tissue was sectioned at 12 μM using frozen slicer (LEICA #CM1850 Germany). Sections were then stained with hematoxylin and eosin (Sigma Aldrich, #SLB59620) and imaged using microscope and stereomicroscope (Nikon, Tokyo, Japan).

2.5. Measurement of Tumor Invasion in the Mouse Model. The extent of tumor invasion in the mouse model was measured in H&E staining images of mouse brain frozen sections, using convexity by the following equation:

\[
\text{Convexity} = \frac{\text{Convex perimeter}}{\text{Perimeter}}
\]

The tumor edge on the images was found using ImageJ: (1) Primary edge finding was done by manually draw along the tumor edge using the magic wand tool, added to ROI, and apply the find edge function. (2) Precise edge finding was done by first adjust the image threshold, then apply the ABS snake plugin utilizing the primary edge found in the 1st step.

Tumor edge was saved as a mask and applied to the original image, and the magic wand tool was used for perimeter measurement. The convex perimeter was measured using the convex hull tool. Three animals from each treatment were subjected to this invasion analysis, and the t-test was applied to compare the convexity of the ITE and DMSO group.

2.6. Organotypic Brain Slice Culture. Mouse brains were extracted from 6-week-old female C57BL/6 mice (euthanized by cervical dislocation) and placed in PBS solution with 3% penicillin and streptomycin in a sterile petri dish. Three percent low melting point agarose (Solarbio, #A8350) solution was prepared and cooled to touch, then poured over the brain, and cooled for an additional 30-45 min. The agarose gel was trimmed, and 300 μM organotypic brain slices were generated using a vibrating microtome ZQP-86 (Zhi Xin Bio-tech, Shang Hai, China). The brain slices were sectioned into two symmetrical halves and transferred to 6-well transwell.
plate chamber by spatula and placed next to each other. Two milliliters of DMEM/F12 medium with 25% FBS was added to the lower chamber and placed in a 37°C and 5% CO₂ incubator for overnight culture.

2.7. Organotypic Brain Slice Invasion Assay. 10⁵ GL261 cells were incubated with CM-Dil (YEASEN, # 40718ES60) for 15 min in 2 μl media, seeded onto the well where two brain slices met, and the brain slices were cultured at the air-liquid interface, with the culture media refreshed every 2-3 days. For drug treatments, serum-free media were added to the lower chamber, with different doses of ITE (0.1 nM, 10 nM, 1000 nM, and 3000 nM) FAK inhibitor PF431396 (MCE, # 717906-29-1) or 0.02% DMSO control. After 5 days and 8 days of continuous culture, cell invasion was observed under a stereomicroscope (Nikon, Tokyo, Japan) for overall slice imaging. For high-resolution imaging, multiple overlapping pictures were taken and stitched together using the software panoramamaker.

2.8. 3D Culture of GL261 Cells. 2 × 10⁵ cells at 50 μl were mixed with 12 μl NaOH, 710 μl complete medium, and 23 μl PBS, as well as 220 μl rat tail tendon collagen type I (PERFEMIKER, #C20-200110). After solidification, supplement 1 ml complete medium was added to the gel. Time-lapse photography was performed using an OlympusXk71 microscope with software Cell Sens Standard, at 30 s intervals for 1 hour. Time-lapse videos were made using ImageJ.

2.9. AHR siRNA Gene Knockdown and Total RNA Extraction. 8 × 10⁵ U87MG cells were seeded into a 6-well plate and transfected when cells grow to 60% confluence according to the manufacturer’s instructions. After 4 hr of transfection, fresh complete medium was added, and total RNA was extracted from the cells after 36 hr transfection using RNA Fastagen Kit (Shanghai Feijie Bio, #220010) according to the manufacturer’s protocol.

2.10. Western Blot. Protein was extracted on ice in RIPA solution (Solarbio, #R0020) and quantified using a bicinchoninic acid protein assay kit (Solarbio, #PC0020). Forty-microgram protein was separated by 8% SDS/PAGE and transferred to the nitrocellulose membranes (MILLIPORE, #HATF00010) at 120 v for 90 min. Membranes were blocked with 5% Skim Milk solution (Solarbio, #D8340) for 3 hr at 37°C, immunoblotted with primary antibody (listed in Supplementary Table 1) overnight at 4°C, washed, then with a secondary antibody, washed, and imaged using ODYSSEY CLX (Clx-0519, LI-COR, Gene Company Limited, USA).

2.11. Transient Transfection of Cells. 8 × 10⁵ U87MG cells were plated into 6-well plates 24 hr before transfection, and the cells were washed and supplemented with 2 ml DMEM before transfection. Plasmid DNA and PEI (ALDRICH, Lot #BCBT0649) were each diluted with MEM/EBSS and allowed to stand for 10 min. The DNA solution was added into the PEI solution and mixed well at N/P = 20, incubated for 10 min. PEI/DNA complexes were added to the cells and replaced by fresh medium after 3.5 hr. The empty vector was employed as a control. MYH9 transgene expression was verified using real-time PCR.

2.12. Real-Time PCR. Four hundred nanograms of total RNA was employed for cDNA synthesis using ProtoScript II First Strand cDNA Synthesis kit (TaKaRa, #RR036A) according to the manufacturer’s protocol. Forty nanograms of cDNA was used as templates for RT-PCR using the SYBR® Premix Ex Taq kit (TaKaRa, #RR820A) using Light Cycler W 480 (Roche, Switzerland). The sequences and efficiency of all primers were listed in Supplementary Table 2, and HPRT/GAPDH was used as reference genes.

2.13. Statistical Analysis. All data were presented as the mean ± standard deviation. One-way ANOVA was utilized to determine the statistical significance of the differences in GL261 and U87MG cell migration, invasion, and western blot analysis. A repeated-measure ANOVA was used to analyze how AHR siRNA and different ITE doses affect cell migration. Data were expressed as means ± SD. The results are displayed as the mean ± standard deviation for n ≥ 3 samples per group in all cases, and P < 0.05 was considered significant differences.

3. Results

3.1. ITE Inhibited Glioma Migration and Invasion In Vitro, Ex Vivo, and In Vivo. We investigated ITE’s effects on glioma cells using wound-healing migration and transwell invasion assays. 100, 1000, and 10000 nM ITE significantly inhibited U87MG and GL261 migration (Figures 1(a) and 1(b)). We further tested ITE’s effects on cell invasion using the Boyden chamber assay and applied a known invasion blocking small-molecule new drug candidate, and FAK inhibitor PF431396 as a positive control. 10 nM ITE significantly inhibited both U87MG and GL261 cell invasion (Figures 1(c) and 1(d)).

We knocked down AHR expression in U87MG cells by siRNA (Figures 1(e)–1(f)) and found that 100, 1000, and 10000 nM ITE significantly inhibited cell migration in the nontargeting control (NC) siRNA group, showing similar efficacy as in untransfected cells. In the AHR siRNA knockdown group, migration was significantly reduced in the DMSO, 0.1, 1, and 10 nM ITE groups, highlighting AHR’s role in regulating glioma cell migration. In AHR knockdown cells, higher ITE doses (100, 1000, and 10000 nM) failed to further inhibit cell migration in siRNA-transfected cells, indicating that ITE’s effect depended on sufficient AHR expression level (Figure 1(g)).

To test whether ITE can block invasion into the brain parenchyma, we performed ex vivo brain invasion assay using live-cell dye CM-Dil labeled GL261 cells (Figures 2(a) and 2(b)). We found that ITE significantly inhibited GL261’s invasion into the normal mouse brain parenchyma at 10 nM, showing a high efficacy compared to the positive control drug PF431396, corroborating that ITE was a potent inhibitor for glioma cell invasion.

We tested whether ITE can block invasion in an orthotopic mouse model of glioma using GL261 cells injected into the front lobe of the mouse brain (Figure 2(c)). Typical
Figure 1: Continued.
Figure 1: Continued.
glioma invasion patterns were observed in this model, including into the peritumor parenchyma, toward the ventricles or toward the blood vessels (Figure 2(d)). Locally at tumor edges, ITE-treated tumors shown more smooth edge hence less invasion into the parenchyma (Figure 2(e)). For tumor edges, ITE-treated tumors shown more smooth edge or toward the blood vessels (Figure 2(d)). Locally at including into the peritumor parenchyma, toward the ventricle glioma invasion patterns were observed in this model, highly significant with statistical difference between groups; * or & P < 0.05, ** or 0.01, and *** or < 0.001).

3.2. ITE Inhibited Polarity, Protrusion Attachment and Rear Contraction of 3D Cultured Cells. As the first step of the mechanistic study, we plated glioma cells in the type I collagen matrix, treated them with ITE or DMSO for 20 hr, the same duration we adopted in the in vitro migration/invasion assays. While the DMSO cells were polarized, only spherical nonmotile cells that continuously bleb were observed (Video.3A-B). To rule out the possibility of apoptosis, we performed a CCK experiment using the same dose and duration (Supplemental Figure 1) and continuously photographed these spherical cells for 3 hr. No sign of apoptosis was observed in either the CCK experiment or the cell behavior under a microscope. Sign of cellular polarization such as a stable large bleb on one side or multiple dynamic blebs on all but one side of the cells was not seen in these cells, indicating that ITE treatment prevented cell polarization.

Shorter (1 hr) ITE treatment provoked cytoskeletal changes in U87MG cells. The more spreading cell body and frequent filopodia extension and retraction were observed (Video. 3C-D). In the control group, when a prominent lamellipodium-like protrusion detached, a shake of the extracellular matrix was observed (Video. 3C), indicating a strong attachment, which was not found in the ITE-treated group (Video. 3D). Furthermore, the prevalent protrusion of ITE-treated cells has more vibrant ruffles at the tip, confirming an unstable attachment to the ECM.

Efficient mesenchymal migration was observed in the control group cells, overcoming constrictions in the matrix (Video. 3E). However, in the ITE-treated cells, the cell rear remains attached to the ECM while its front part moves forward, resulted in cells with an elongated rear (Video. 3F), indicating compromised cellular contraction.

3.3. ITE Inhibited Switching to the Amoeboid Migration Modes. In the DMSO 1 hr treatment group, we observed mesenchymal migrating cells started to bleb when encountering matrix constrictions (Video. 3E). Moreover, the A1 mode of the amoeboid migration, characterized by a prominent leading protrusion and round cell shape, was also observed [9] (Video. 3A), indicating that cells could swiftly switch to amoeboid migration when encountering space restrictions. No such phenomenon was observed in the ITE-treated group, and typical cells still adopted the elongated shape (Video.3F).

Accordingly, ITE-treated cells in 2D culture also failed to undergo amoeboid migration when subject to pH changes.
Figure 2: Continued.
When taken out of the incubator for 2 hr photography, the culture medium became basic and U87MG cells responded to the pH change by becoming spherical and migrating, which is evident in the overlapping photos taken at the beginning and end of the photography period (Figure 3(g), Video 3I). ITE-treated cells remained in the same position and maintained the same shape failed to respond (Figure 3(h), Video 3J). The few spherical cells in the ITE-treated group also lack the sign of polarity.

3.4. MYH9 Mediated ITE Migration-Inhibiting Effects in Human Glioma Cells. Since ITE-treated cells display cytoskeletal changes, we studied related molecules. Several integrin, collagen, and FAK were examined by either RT-PCR or western blot, and none showed significant changes (Supplemental Figure 2A-D). To identify the genes that mediated ITE’s invasion-inhibition effects, we compared gene expression profiles of ITE versus DMSO-treated U87MG and GL261 cells. Candidate genes were filtered by comparing the differently expressed genes from our experiment, a reported glioma migration-related gene set, and reported AHR-regulated genes. The genes in common contained mainly TGF beta pathway members and MYH9 (Supplemental Figure 3A, Table 3). No significant changes in Smad2/3 protein were detected when comparing ITE to DMSO-treated U87MG cells (Supplemental Figure 3B), and MYH9 was further studied.

MYH9, a component of the nonmuscle myosin IIA (NMIIA), was significantly reduced by various doses of ITE treatment (0.1, 1, 10, 100, and 1000 nM) in U87MG cells.
both by RT-PCR and western blot analysis (Figures 4(a) and 4(b)). To confirm the relationship between ITE and MYH9, we transfected into the cells with MYH9 cDNA fused to mCherry. Imaging, RT-PCR, and western blot confirmed elevated MYH9 levels in transfected cells (Figures 4(c)–4(e)). Again, various doses of ITE (0.1, 10, and 1000 nM) significantly reduced MYH9 mRNA expression in both groups (Figure 4(f)), indicating that ITE inhibited MYH9 expression across a wide background expression range.

We examined the RNA-seq data to see whether AHR was activated upon ITE binding. In expression levels of classical AHR target, cytochrome family members remained unchanged in ITE-treated group (Supplemental Table. 4). Gene set enrichment analysis was done to check the AHR pathway, which was not significant, either (Supplemental Figure.4).

We further analyzed the relationship between MYH9 level and cell migration by treating MYH9 overexpressing cells with various ITE doses and measured their migration ability (Figure 4(g)). In addition to ITE’s migration-inhibition effects in both groups, we found that MYH9 expression level correlated well with cell migration ability (Figure 4(h)), indicating that ITE’s migration-inhibition effects were mediated by MYH9 at least partly.

4. Discussion

Drugs that can block cancer cell invasion are urgently sought after, and we discovered that ITE, an endogenous ligand of AHR, could block migration of the glioma cells ex vivo and in vivo, supporting ITE to be investigated as a lead compound. We identified a previously unknown target of AHR and MYH9, providing clues on how AHR regulates migration in human glioma cells. MYH9 is essential for both mesenchymal and amoeboid migration, and accordingly, we observed compromised cell migration and invasion. ITE’s migration-inhibition effect had a nonmonotonic dose-response which was common in endocrine disruptors and has been seen in TCDD-treated cells [10]. Another factor that might contribute to the nonmonotonic dose-response was the tryptophan in the culture medium (25 μM), whose metabolite kynurenine is an AHR ligand. The affinity of kynurenine (32 μM) to AHR is lower compared to ITE (3 nM), and it is conceivable that ITE, especially at higher doses, dominated AHR’s effects.

AHR either activates or inhibits cell migration, depending on the ligand and cellular context. AHR ligands, indirubin or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), activate the AHR pathway, upregulated the expression of AHR and
Figure 4: Continued.
CYPs, and promoted the renal cell carcinoma invasion by upregulating MMPs [11]. Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal cell carcinoma and is associated with poor prognosis and cigarette smoke. Kynurenine, the endogenous ligand of the AHR, could either activate triple-negative breast cancer cell migration [12] or inhibit neuroblastoma cell migration to activate AHR [13]. Additional AHR ligands that have been reported for migration-inhibition effects include quercetin, omeprazole, indirubin, and 3-methylcholanthrene (3-MC). 20 μM quercetin inhibits U87 glioma cell invasion, 300 μM omeprazole inhibits breast cancer metastasis, 5 μM indirubin inhibits glioma invasion, and 1 mM 3-MC inhibits human umbilical vascular endothelial cell (HUVEC) migration.
These ligands’ effective concentration varies from several to hundreds of micromolar [14–17]. ITE inhibits glioma cell migration at nanomolar concentrations, exhibiting a significantly higher efficacy.

Various migration-related pathways were regulated by ligand-bound AHR, including phospholipase D1, CXCR4, and FAK. AHR antagonist quercetin inhibited U87MG cells’ invasion via downregulating phospholipase D1, omeprazole inhibited breast cancer metastasis in a mouse model and cancer patients via downregulation of the AHR-CXCR4 signaling pathway [14], indirubin inhibited glioma invasion in a mouse model via inhibition of GSK3beta [17], and AHR agonist 3-MC inhibited HUVEC migration by reducing FAK activity.

We found that ITE inhibited migration and invasion via the AHR-MYH9 axis, supporting MYH9 as a novel AHR target. Neither classical AHR target cytochrome genes nor the AHR signaling pathway showed significant changes/enrichment. How AHR regulates MYH9 warrants further study.

Most of the observed U87MG cell behavior upon ITE treatment could be explained by weakened actomyosin contraction due to lowered MYH9/NMIIA level. We observed compromised rear attraction, polarity, and mode switching in ITE-treated glioma cells in vitro. Cell spreading and protrusion dynamics are the net results of the centrifugal force generated by actin polymerization and the centripetal force generated by actomyosin contraction [18, 19]; so, with lower actin-myosin contraction resulted from lower MYH9, both cells spreading and filopodia extension increased, especially at the lateral side of the cell, as NMIIA inhibited lateral filopodia formation and maintained cell polarity. The weakened protrusion tip attachment probably resulted from lowered NMIIA too, as inhibition/knockdown NMIIA resulted in a reduction of the filopodia attachment strength [20], and inefficient lamellipodia attachment caused the ruffles [21]. Cell rear retraction depends on myosin II, which explained the inefficient rear retraction upon ITE treatment [22]. All these changes are similar to what was reported in cancer cells with depleted or lowered NMIIA [23, 24]. Moreover, the 20 hr ITE treatment caused cells to adopt a spherical shape, which was like what is shown in NMIIA knockdown cells after 12 hr in collagen matrix.

The inhibition of the mesenchymal to amoeboid transition in both 2D and 3D culture could have resulted from the lower MYH9 expression level upon ITE treatment. Cells need actomyosin contraction to become spherical [25]; hence, most of the ITE-treated cells remained in its original polygon shape. The inefficient blebbing amoeboid mode manifested as a lack of polarity is probably also due to the lower MYH9, which is needed to form a cell rear [26]. Blebs forming and retracting continuously in the round amoeboid migration, yet there is a lack of blebbing at the rear, which is essential for cell polarity.

Among the four possible cancer cell migration modes, we discovered that ITE inhibited both mesenchymal and the characteristic amoeboid A1 migration mode [27]. In GBM, to migrate in the brain, glioma cells have to squeeze through pores smaller than its cell body size, often with the help of matrix metalloproteinase where NMIIA is essential [28, 29] too. The reason for the lack of A1 mode in the ITE-treated group needs further investigation. Moreover, MYH9 promotes tumor progression by modulating the immune microenvironment, so reduced MYH9 level by ITE treatment potentially offers immune-promoting benefit in addition to its invasion-inhibiting effects [30].

When writing this paper, it is reported that programmed death-ligand1 (PDL1)/programmed cell death protein 1(PD1) blockade was effective as neoadjuvant therapy in GBM. The combination of ITE and PD1/PDL1 blockade warrants further research.

5. Conclusion

Small molecular AHR agonist ITE regulated glioma cells’ migration via binding to AHR and inhibited the actin-myosin contraction due to reduced MYH9 protein level (Figure 5). ITE efficiently blocked glioma invasion in vitro, ex vivo, and in vivo in an orthotopic mouse glioma model.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This work was supported by the National Natural science Foundation of China (grant 81460455). We thank Dr. Jun Dong (Suzhou University) who kindly taught us on how to build the orthotopic glioma model and Professor Xiaomei Zhu from (Shanghai University) who provided insight and expertise that greatly assisted the research.
Supplementary Materials

Table S1: list of primary antibodies used for western blotting. Table S2: list of primer sequences. Figure S1: Proliferation of U87MG up on ITE treatment. Figure S2: COCL1, ITGA5, ITGB5 and FAK levels expression level changes upon ITE treatment. Figure S3: Venn diagram of migration related, AHR regulated, and ITE-affected genes and SMAD2/3 protein levels in human glioma U87MG cells upon ITE treatment. Table S3: list of intersection genes. Sup Figure S4: Gene set enrichment analysis were done to check AHR pathway. Supplementary Table S4 List of cytochrome family members. Video S3: full videos of Figures. (Supplementary Materials)

References

[1] D. R. Johnson and B. P. O’Neill, “Glioblastoma survival in the United States before and during the temozolomide era,” Journal of Neuro-Oncology, vol. 107, no. 2, pp. 359–364, 2012.
[2] L. N. Agbor, K. M. Elased, and M. K. Walker, “Endothelial-specific aryl hydrocarbon receptor knockout mice exhibit hypotension mediated, in part, by an attenuated angiotensin II responsiveness,” Biochemical Pharmacology, vol. 82, no. 5, pp. 514–523, 2011.
[3] C. R. Filbrandt, Z. Wu, B. Zlokovic, L. Opanashuk, and T. A. Gasiewicz, “Presence and functional activity of the aryl hydrocarbon receptor in isolated murine cerebral vascular endothelial cells and astrocytes,” Neurotoxicology, vol. 25, no. 4, pp. 605–616, 2004.
[4] Y. H. Lee, C. H. Lin, P. C. Hsu et al., “Aryl hydrocarbon receptor mediates both proinflammatory and anti-inflammatory effects in lipopolysaccharide-activated microglia,” Glia, vol. 63, no. 7, pp. 1138–1154, 2015.
[5] U. Jin, K. Karki, Y. Cheng, S. K. Michelhaugh, S. Mittal, and S. Safe, “The aryl hydrocarbon receptor is a tumor suppressor-like gene in glioblastoma,” Journal of Biological Chemistry, vol. 294, no. 29, pp. 11332–11333, 2019.
[6] C. A. Opitz, U. M. Litzenburger, F. Sahm et al., “An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor,” Nature, vol. 478, no. 7368, pp. 197–203, 2011.
[7] E. Ladomersky, L. Zhai, A. Lenzen et al., “IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma,” Clinical Cancer Research, vol. 24, no. 11, pp. 2559–2573, 2018.
[8] N. P. Taylor, “Pfizer drops ITeos IDO1 cancer drug due to lack of efficacy,” https://www.fiercebiotech.com/biotech/pfizer-drops-iteos-ido1-cancer-drug-due-to-lack-efficacy.
[9] Y. Liu, M. le Berre, F. Lautenschlaeger et al., “Confinement and low adhesion induce fast amoeboid migration of slow mesenchymal cells,” Cell, vol. 160, no. 4, pp. 659–672, 2015.
[10] M. H. Ziccardi, I. A. Gardner, and M. S. Denison, “Development and modification of a recombinant cell bioassay to directly detect halogenated and polycyclic aromatic hydrocarbons in serum,” Toxicological Sciences, vol. 54, no. 1, pp. 183–193, 2000.
[11] M. Ishida, S. Mikami, T. Shinojima et al., “Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal cell carcinoma and is associated with poor prognosis and cigarette smoke,” International Journal of Cancer, vol. 137, no. 2, pp. 299–310, 2015.
[12] O. Novikov, Z. Wang, E. A. Stanford et al., “An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER/PR−Her2 human breast cancer cells,” Molecular Pharmacology, vol. 90, no. 5, pp. 674–688, 2016.
[13] P. Y. Wu, I. S. Yu, Y. C. Lin et al., “Activation of aryl hydrocarbon receptor by kynurenine impairs progression and metastasis of neuroblastoma,” Cancer Research, vol. 79, no. 21, pp. 5550–5562, 2019.
[14] U. Jin, S. Lee, C. Pfent, and S. Safe, “The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis,” BMC Cancer, vol. 14, no. 1, pp. 498–498, 2014.
[15] M. H. Park and S. Min, “Quercetin-induced downregulation of phospholipase D1 inhibits proliferation and invasion in U87 glioma cells,” Biochemical and Biophysical Research Communications, vol. 412, no. 4, pp. 710–715, 2011.
[16] B. Y. Wang, J. Zhang, J. L. Wang et al., “Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer,” Journal of Experimental & Clinical Cancer Research, vol. 34, no. 1, 2015.
[17] S. P. Williams, M. O. Nowicki, F. Liu et al., “Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments,” Cancer Research, vol. 71, no. 16, pp. 5374–5380, 2011.
[18] T. Wakatsuki, R. W. Wolsymerski, and E. L. Elson, “Mechanics of cell spreading: role of myosin II,” Journal of Cell Science, vol. 116, no. 8, pp. 1617–1625, 2003.
[19] T. Bornschlogl, S. Romero, C. L. Vestergaard, J. F. Joanny, G. T. van Nhieu, and P. Bassereau, “Filopodial retraction force is generated by cortical actin dynamics and controlled by reversible tethering at the tip,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 47, pp. 18928–18933, 2013.
[20] N. O. Alieva, A. K. Efremov, S. Hu et al., “Myosin IIA and formin dependent mechanosensitivity of filopodia adhesion,” Nature Communications, vol. 10, no. 1, p. 3593, 2019.
[21] B. Borm, R. P. Requardt, V. Herzog, and G. Kirschf, “Membrane ruffles in cell migration: indicators of inefficient lamellipodia adhesion and compartments of actin filament reorganization,” Experimental Cell Research, vol. 302, no. 1, pp. 83–95, 2005.
[22] M. Vicente-Manzanares, J. Zareno, L. Whitmore, C. K. Choi, and A. F. Horwitz, “Regulation of protrusion, adhesion dynamics, and polarity by myosins IIA and IIB in migrating cells,” Journal of Cell Biology, vol. 176, no. 5, pp. 573–580, 2007.
[23] M. Vicente-Manzanares, X. Ma, R. S. Adelstein, and A. R. Horwitz, “Non-muscle myosin II takes centre stage in cell adhesion and migration,” Nature Reviews Molecular Cell Biology, vol. 10, no. 11, pp. 778–790, 2009.
[24] N. O. Alieva, A. K. Efremov, S. Hu et al., “Force dependence of filopodia adhesion: involvement of myosin II and formins, no. - article 195420, 2017BioRxiv, 2017.
[25] V. Ruprecht, S. Wieser, A. Callan-Jones et al., “Cortical contractility triggers a stochastic switch to fast amoeboid cell motility,” Cell, vol. 160, no. 4, pp. 673–685, 2015.
[26] M. Vicente-Manzanares, K. Newell-Litwa, A. I. Bachir, L. A. Whitmore, and A. R. Horwitz, “Myosin IIA/IIB restrict adhesive and protractive signaling to generate front–back polarity in migrating cells,” Journal of Cell Biology, vol. 193, no. 2, pp. 381–396, 2011.
[27] C. D. Paul, P. Mistriotis, and K. Konstantopoulos, "Cancer cell motility: lessons from migration in confined spaces," *Nature Reviews Cancer*, vol. 17, no. 2, pp. 131–140, 2017.

[28] E. Sahai and C. J. Marshall, "Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis," *Nature Cell Biology*, vol. 5, no. 8, pp. 711–719, 2003.

[29] R. Ferrari, E. Infante, and P. Chavrier, "Nucleus–invadopodia duo during cancer invasion," *Trends in Cell Biology*, vol. 29, no. 2, pp. 93–96, 2019.

[30] M. Georgouli, C. Herraiz, E. Crosas-Molist et al., "Regional activation of myosin II in cancer cells drives tumor progression via a secretory cross-talk with the immune microenvironment," *Cell*, vol. 176, no. 4, pp. 757–774.e23, 2019.